文献速递肥胖与代谢综合征糖尿病

评估减重药物直接组织效应与减重效应对多种慢性疾病的影响

Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions.
PubMed 文献 · Lancet Diabetes Endocrinol · 2025-01-24

本文探讨减重药物通过减重与直接组织效应改善疾病结局的相对贡献,认为减重至少部分解释了其对射血分数保留的心力衰竭、高血压、慢性肾脏病和2型糖尿病的获益,而对骨关节炎、阻塞性睡眠呼吸暂停和代谢功能障碍相关脂肪性肝炎的改善主要由减重驱动,需更多证据验证。

要点

  • 减重药物对主要不良心血管事件的减少主要归因于直接组织效应,但减重效应在其他结局中的作用程度不同。
  • 减重至少部分解释了减重药物对射血分数保留的心力衰竭、高血压、慢性肾脏病和2型糖尿病的获益。
  • 减重药物对骨关节炎、阻塞性睡眠呼吸暂停和代谢功能障碍相关脂肪性肝炎的改善主要由减重驱动。

核心结论

  • 减重至少部分解释了减重药物对射血分数保留的心力衰竭、高血压、慢性肾脏病和2型糖尿病的获益,程度各异。
  • 减重药物对骨关节炎、阻塞性睡眠呼吸暂停和代谢功能障碍相关脂肪性肝炎的改善主要由减重驱动。
  • 需要更多证据巩固这些观察,包括比较减重药物与热量限制饮食对结局和机制通路影响的试验。

研究设计与样本

  • 本文为个人观点(Personal View),基于现有证据进行论述。

主要发现

  • 主要不良心血管事件的减少似乎主要由减重药物的直接组织效应驱动。
  • 减重至少部分解释了减重药物对射血分数保留的心力衰竭、高血压、慢性肾脏病和2型糖尿病的获益,程度各异。
  • 减重药物对骨关节炎、阻塞性睡眠呼吸暂停和代谢功能障碍相关脂肪性肝炎的改善主要由减重驱动。

局限性

  • 原文指出需要更多证据来巩固这些观察,包括在可能时开展比较减重药物与热量限制饮食对结局和机制通路影响的试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct effects of these drugs is the subject of intense interest. Although reductions in major adverse cardiovascular events appear to be predominantly driven by the direct tissue effects of such drugs, the associated weight loss effects must be relevant to the benefits observed in other major outcomes, albeit to differing extents. In this Personal View, we draw on evidence to support that weight loss is at least partly responsible (albeit to differing extents) for the reported benefits of incretin-based drugs for obesity in people living with heart failure with preserved ejection fraction, hypertension, chronic kidney disease, and type 2 diabetes. Concurrently, we propose that drug-induced weight loss is largely responsible for the reported improvements in osteoarthritis, obstructive sleep apnoea, and metabolic dysfunction-associated steatohepatitis outcomes. However, more evidence is needed to solidify these observations, including, when possible, trials comparing the effects of incretin-based drugs for obesity with calorie-reduced diets on both outcomes and mechanistic pathways. Such evidence has implications for public health and the design of future trials of novel drugs for obesity.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Sattar N, Lee MMY. Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions. Lancet Diabetes Endocrinol. 2025. PMID: 39870097. doi:10.1016/S2213-8587(24)00363-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。